Lingering questions for each of your countries health regulators about the C19 injection roll-out

1.      What evidence did you have that using mRNA instructions to manufacture the spike protein would cause the already weakened and compromised immune systems of the elderly and infirm to mount an immune response?

2.      During your review of safety and efficacy data from the Phase 3 Pfizer C19 mRNA injection clinical trial what differences did you observe from the analysis shown on pages 11 and 12 of the slide deck linked below:

The COVID-19 Inoculations - More Harm Than Good FINAL Video & Print (canadiancovidcarealliance.org)

3.      The Pfizer Phase 3 clinical trial was unblinded months before the scheduled trial end date of 31 January 2021. You granted Emergency Use Authorization on 10 December 2020. What were your reasons for allowing  clinical trial results to be valid after unblinding the clinical trial and approving under EUA 52 days early for a 192 day trial?

4.      What follow-up infection and adverse event information did Pfizer provide you on each individual in  each of the control and placebo groups after the trial was unblinded 52 days before its 6 month intended duration?

5.      The sole pre-specified end point of the clinical trials of the C19 injections was to reduce the severity of symptoms. Two other clinical end points  – the prevention of transmission or infection and reduction in hospitalizations or deaths – were not required. Why did you not alert the general public to this and why did you not insist that the manufacturers disclose this fact in order to facilitate informed consent?

In the post marketing authorization report here:

reissue_5.3.6-postmarketing-experience.pdf (phmpt.org)

Note that although 126 million doses may have been shipped, less than 70 million doses were probably administered. You can see that the vast majority of the 41,086 case reports for 168,895 events were in the US and EU countries.

Using data from here and here, the number of doses administered to end February 2021 were 38 million for the US and 29 million for the EU – a total of 67 million compared to the 126 million shipped. The inference could be drawn that 63 million people had received both doses of the Pfizer C19 mRNA injection based on the number of doses shipped, when in fact 33.5 million people actually received the initial two dose course of injections.

6.      Did you assess the adverse event ratio (events to people or events to doses) to reflect this difference between doses shipped and doses administered?

7.      Did you reconcile the rate of adverse events reported in the Phase 3 clinical trial with this (short) 3 month post marketing authorization report to gauge how many reports for adverse events were NOT included in Pfizer’s post marketing authorization report to 28 February 2021? What follow up instructions did you give to Pfizer for the 9,400 “Unknown” outcomes or the 11,361 “Not recovered” or the progress of the 20,000 “Recovering” or recovered out of the 42,086 reports on individuals?

For example, the Pfizer Phase 3 clinical trial data indicated a rate of 5,241 adverse events amongst 21,921 in the injected group – a rate of 24%. There were 262 severe (life altering) adverse events in the injected group – a rate of 1.2% amongst those who had completed the initial series. There were 127 serious (life threatening) events – 0.6%.

For the 33.5 million people injected with two doses of Pfizer/BioNTech C19 mRNA (initial series of injections) over the (short) 3 month post marketing authorization report, there would have been over 8 million adverse events, 400,000 severe adverse events and 200,000 serious adverse events.

The same questions apply to clinical trials for Moderna, Johnson and Johnson, AstraZeneca and any others.

8.      How many vials containing doses of C19 injections shipped did you test to ensure the contents matched the contents of the clinical trial doses? How often did you repeat these tests – daily, weekly, quarterly or six monthly? After completing these tests, if any, how many vials did you reject?

There are lots more questions around the fraud and negligence in the clinical trials that are in the link above. We will be getting the Moderna post marketing authorization report shortly for the US.

One of the largest outstanding issues not touched by any study is the impact on C19 injections on other drugs being taken by people in the general population - by age and gender. Nor are we yet focussing on this impact months or years after injections. Would any adverse events be ascribed to the non-C19 drugs or to the C19 injections?

Each country’s health regulator had access to this information – or should have.

We know that contracts negotiated with Pfizer et al, basically said “we will supply, but not guarantee anything, that is down to you as the representative government and regulator”.

Hopefully, the answers to these questions will result in another “NEVER AGAIN” paradigm.

Onwards!

Please upgrade to paid, or donate a coffee (I drink a lot of coffee) - “God Bless You!” if you can’t or don’t want to contribute. Coffee donations here: https://ko-fi.com/peterhalligan  - Buying just one Ko-fi a week  for $3 is 50 bucks more than an annual $100 subscription!